J Korean Diabetes.  2014 Mar;15(1):24-29. 10.4093/jkd.2014.15.1.24.

The Management of Metabolically Unhealthy Obesity

• Lee JH
• Ku BJ

• KMID: 1703379
• DOI: http://doi.org/10.4093/jkd.2014.15.1.24

Abstract

Increasing rates of obesity are related to increasing incidence of metabolic diseases such as type 2 diabetes, hypertension and cardiovascular disease. The need to prevent and treat obesity is an obvious way to reduce its incidence and to reduce the complications associated with metabolic diseases. To reduce the risk of cardiovascular disease in obese adults, it is important not only to lose weight but to manage preexisting metabolic disease. Therefore, a systematic and organized approach is needed for the management of obesity with metabolic disease.

Keyword

Obesity; Metabolic diseases; Cardiovascular diseases; Disease management

MeSH Terms

Adult
Cardiovascular Diseases
Disease Management
Humans
Hypertension
Incidence
Metabolic Diseases
Obesity*

Reference

References

1. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. The Fifth Korea National Health and Nutritional Examination Survey (KNHANES V) 2010 [Internet]. Cheongwon: Ministry of Health and Welfare;c2012. [cited 2014 Jan 27]. Available from:. http://knhanes.cdc.go.kr.

2. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013 Nov 12. [Epub].http://dx.doi.org/10.1161/01.cir.0000437739.71477.ee.

3. Korean Society for the Study of Obesity. Treatment guideline of obesity 2012. Seoul: Korean Society for the Study of Obesity;2012.

4. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010; 12:941–6.

5. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med. 2007; 147:41–50.

6. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and metaanalysis of weight-loss clinical trials with a minimum 1-year followup. J Am Diet Assoc. 2007; 107:1755–67.

7. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. The Fifth Korea National Health and Nutritional Examination Survey (KNHANES V) 2012 [Internet]. Cheongwon: Ministry of Health and Welfare;c2012. [cited 2014 Jan 27]. Available from:. http://knhanes.cdc.go.kr.

8. Geliebter A, Maher MM, Gerace L, Gutin B, Heymsfield SB, Hashim SA. Effects of strength or aerobic training on body composition, resting metabolic rate, and peak oxygen consumption in obese dieting subjects. Am J Clin Nutr. 1997; 66:557–63.

9. Sum CF, Wang KW, Choo DC, Tan CE, Fok AC, Tan EH. The effect of a 5-month supervised program of physical activity on anthropometric indices, fat-free mass, and resting energy expenditure in obese male military recruits. Metabolism. 1994; 43:1148–52.

10. Katzel LI, Bleecker ER, Rogus EM, Goldberg AP. Sequential effects of aerobic exercise training and weight loss on risk factors for coronary disease in healthy, obese middle-aged and older men. Metabolism. 1997; 46:1441–7.

11. Kraemer WJ, Adams K, Cafarelli E, Dudley GA, Dooly C, Feigenbaum MS, Fleck SJ, Franklin B, Fry AC, Hoffman JR, Newton RU, Potteiger J, Stone MH, Ratamess NA, Triplett-McBride T. American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2002; 34:364–80.

12. American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998; 30:975–91.

13. American College of Sports Medicine. ACSM's exercise management for persons with chronic diseases and disabilities. 3rd ed.Champaign: Human Kinetics;2009.

14. World Health Organization Western Pacific Region. The Asia-Pacific perspective: redefining obesity and its treatment. St. Leonards: Health Communications Australia;2000.

15. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, Samet JM. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006; 355:779–87.

16. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO, Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H, Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G, Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y, Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011; 364:719–29.

17. McNeely W, Benfield P. Orlistat. Drugs. 1998; 56:241–9.

18. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281:235–42.

19. Shekelle PG, Morton SC, Maglione M, Suttorp M, Tu W, Li Z, Maggard M, Mojica WA, Shugarman L, Solomon V. Pharmacological and surgical treatment of obesity. Evid Rep Technol Assess (Summ). 2004; 103:1–6.

20. U.S. Food and Drug Administration. FDA breifing document: NDA 22529 Lorqess (lorcaserin hydrochloride) tablets, 10 mg. Silver Spring: U.S. Food and Drug Administration;2010.

21. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363:245–56.

22. Kasama K, Mui W, Lee WJ, Lakdawala M, Naitoh T, Seki Y, Sasaki A, Wakabayashi G, Sasaki I, Kawamura I, Kow L, Frydenberg H, Chen A, Narwaria M, Chowbey P. IFSO-APC consensus statements 2011. Obes Surg. 2012; 22:677–84.

23. Perri MG, McAllister DA, Gange JJ, Jordan RC, McAdoo G, Nezu AM. Effects of four maintenance programs on the longterm management of obesity. J Consult Clin Psychol. 1988; 56:529–34.

24. Acheson KJ. Carbohydrate for weight and metabolic control: where do we stand? Nutrition. 2010; 26:141–5.

25. Joslin Diabetes Center and Joslin Clinic. Clinical nutrition guideline for overweight and obese adults with type 2 diabetes, predeiabetes or those at high risk for developing type 2 diabetes. Boston: Joslin Diabetes Center;2011.

26. Korean Diabetes Association Committee of Clinical Practice Guidline. Treatment guideline for diabetes 2013. Seoul: Korean Diabetes Association;2013.

27. Korean Society of Lipidology and Atherosclerosis. Treatment guideline of dyslipidemia. Seoul: Korean Society of Lipidology and Atherosclerosis;2009.

28. Korean Society of Hypertension. Treatment guideline of hypertension 2013. Seoul: Korean Society of Hypertension;2013.

29. Ruderman N, Devlin JT, Schneider SH, Kriska AM. Handbook of exercise in diabetes. 2nd ed.Alexandria: American Diabetes Association;2002. p. 401–13.

30. Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA, de Jesus JM, Sacks FM, Lee IM, Smith SC Jr, Lichtenstein AH, Svetkey LP, Loria CM, Wadden TW, Millen BE, Yanovski SZ. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7. [Epub].http://dx.doi.org/10.1016/j.jacc.2013.11.003.

31. U.S. Department of Health and Human Services. Physical activity guidelines advisory committee report, 2008. Washington D.C.: U.S. Department of Health and Human Services;2008.

32. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J, Grant AM. Weight loss in obese diabetic and non-diabetic individuals and longterm diabetes outcomes – a systematic review. Diabetes Obes Metab. 2004; 6:85–94.

33. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the longterm effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004; 8:iii–iv. 1–182.

34. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev. 2005; (2):CD005270.

35. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481–6.

36. Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, Lau J. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005; (2):CD004095.

37. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; (1):CD004096.

38. Poobalan A, Aucott L, Smith WC, Avenell A, Jung R, Broom J, Grant AM. Effects of weight loss in overweight/obese individuals and longterm lipid outcomes – a systematic review. Obes Rev. 2004; 5:43–50.

39. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and longterm hypertension outcomes: a systematic review. Hypertension. 2005; 45:1035–41.